flanders.bio is an independent life sciences cluster organisation based in Flanders, Belgium

flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.

News from flanders.bio and its members

MDxHealth Announces Presentation of Positive Data for SelectMDx and ConfirmMDx in Prostate Cancer Diagnosis

MDxHealth SA (Euronext: MDXH.BR) today announced that positive data and observations from multiple studies and patient registries demonstrating the value of SelectMDx and ConfirmMDx for Prostate Cancer diagnosis, will be presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place in San Francisco, California, February 14-16, 2019.

Research | 15 February 19 Read more

MDxHealth (R): MDxHealth Signs Partnership with LifeLabs to Make SelectMDx available in Canada

MDxHealth SA (Euronext: MDXH.BR) today announces that it has signed an exclusive distribution agreement with LifeLabs to make SelectMDx®, the Company's non-invasive liquid biopsy prostate cancer test, available in Canada. LifeLabs is a leading Canadian company that performs over 100 million laboratory tests per year to help diagnose, treat, monitor and prevent diseases, supporting over 19 million patient visits annually.

14 February 19 Read more

Mithra Successfully Produces its First Commercial Batch of Myring™ for Europe

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces today that its development and production center has successfully produced its first commercial batch of Myring™ for the European market. This first order of the vaginal contraceptive ring will be sold in the Czech Republic, a market worth approximately EUR 1.3 million[1]. This production follows a 10-year non-exclusive license and supply agreement with the Polish company Adamed Group (Adamed) in December 2017.

First patient recruited in collaborative Phase 1 study to evaluate TriMix in breast cancer patients

VUB, the Vrije Universiteit Brussel, and eTheRNA immunotherapies, a clinical-stage company developing cancer immunotherapies based on its proprietary mRNA-based TriMix platform, announce the recruitment of the first patient for a collaborative TriMix-BRE study to investigate the effect of the TriMix product as neo-adjuvant treatment (treatment before planned surgery) for breast cancer patients. The study will deliver mRNA via intratumoral injection in patients with non-metastatic breast cancer before planned surgery and will recruit patients with resectable breast cancer irrespective of subtype of breast cancer.

flanders.bio events, trainings & international missions

Strategic Partners